Sanam Safi

Sanam Safi

Auto-generated profile, based on publicly available information

Sanam Safi

Department of Cardiothoracic Surgery University Hospital of Copenhagen, Rigshospitalet Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
SKSteven Kwasi Korang
Steven Kwasi Korang
SSSanam Safi
Sanam Safi
CGChristian Nyfeldt Gluud
Christian Nyfeldt Gluud
ULUlrik Lausten-Thomsen
Ulrik Lausten-Thomsen
JJJanus C. Jakobsen
Janus C. Jakobsen
Background: Sepsis is a major cause of morbidity and mortality among neonates and infants. Antibiotics are a central part of the first line treatment for sepsis in neonatal intensive care units worldwide. However, the evidence on the clinical effects of the commonly used antibiotic regimens for sepsis in neonates remains scarce. This systematic review aims to assess the efficacy and harms of antibiotic regimens for neonatal sepsis. Methods: Electronic searches will be conducted in MEDLINE, Embase, The Cochrane Library, CINAHL, ZETOC and clinical trial registries (clinicaltrials.gov and ISRCTN). We will include randomised controlled trials of different antibiotic regimens for sepsis of neonates and infants. Eligible interventions will be any antibiotic regimen. Two reviewers will independently screen, select, and extract data. The methodological quality of individual studies will be appraised following Cochrane methodology. Primary outcomes will be ‘all-cause mortality’ and ‘serious adverse events’. Secondary outcomes will be ‘need for respiratory support’, ‘need for circulatory support’, ‘neurodevelopmental impairment’, ototoxicity, nephrotoxicity and necrotizing enterocolitis. We plan to perform a meta-analysis with trial sequential analysis. Discussion: This is the study protocol for a systematic review on the effects of different antibiotic regimens for neonatal sepsis. The results of this systematic review intent to adequately inform stakeholders or health care professionals in the field of neonatal sepsis, and to aid appropriate development of treatment guidelines. Systematic review registration: PROSPERO reference number: CRD42019134300.

17 December 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SSSanam Safi
Sanam Safi
NSNaqash J Sethi
Naqash J Sethi
ENEmil Eik Nielsen
Emil Eik Nielsen
JFJoshua Feinberg
Joshua Feinberg
JJJanus C Jakobsen
Janus C Jakobsen
CGChristian Nyfeldt Gluud
Christian Nyfeldt Gluud

5 November 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SSSanam Safi
Sanam Safi
NSNaqash J Sethi
Naqash J Sethi
SKSteven Kwasi Korang
Steven Kwasi Korang
ENEmil Eik Nielsen
Emil Eik Nielsen
JFJoshua Feinberg
Joshua Feinberg
JJJanus C Jakobsen
Janus C Jakobsen
Background Cardiovascular disease is the number one cause of death globally. According to the World Health Organization (WHO), 7.4 million people died from ischaemic heart disease in 2012, constituting 15% of all deaths. Beta‐blockers are recommended and are often used in patients with heart failure after acute myocardial infarction. However, it is currently unclear whether beta‐blockers should be used in patients without heart failure after acute myocardial infarction. Previous meta‐analyses on the topic have shown conflicting results. No previous systematic review using Cochrane methods has assessed the effects of beta‐blockers in patients without heart failure after acute myocardial infarction. Objectives To assess the benefits and harms of beta‐blockers compared with placebo or no treatment in patients without heart failure and with left ventricular ejection fraction (LVEF) greater than 40% in the non‐acute phase after myocardial infarction. Search methods We searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index ‐ Expanded, BIOSIS Citation Index, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, European Medicines Agency, Food and Drug Administration, Turning Research Into Practice, Google Scholar, and SciSearch from their inception to February 2021. Selection criteria We included all randomised clinical trials assessing effects of beta‐blockers versus control (placebo or no treatment) in patients without heart failure after myocardial infarction, irrespective of publication type and status, date, and language. We excluded trials randomising participants with diagnosed heart failure at the time of randomisation. Data collection and analysis We followed our published protocol, with a few changes made, and methodological recommendations provided by Cochrane and Jakobsen and colleagues. Two review authors independently extracted data. Our primary outcomes were all‐cause mortality, serious adverse events, and major cardiovascular events (composite of cardiovascular mortality and non‐fatal myocardial reinfarction). Our secondary outcomes were quality of life, angina, cardiovascular mortality, and myocardial infarction during follow‐up. We assessed all outcomes at maximum follow‐up. We systematically assessed risks of bias using seven bias domains and we assessed the certainty of evidence using the GRADE approach. Main results We included 25 trials randomising a total of 22,423 participants (mean age 56.9 years). All trials and outcomes were at high risk of bias. In all, 24 of 25 trials included a mixed group of participants with ST‐elevation myocardial infarction and non‐ST myocardial infarction, and no trials provided separate results for each type of infarction. One trial included participants with only ST‐elevation myocardial infarction. All trials except one included participants younger than 75 years of age. Methods used to exclude heart failure were various and were likely insufficient. A total of 21 trials used placebo, and four trials used no intervention, as the comparator. All patients received usual care; 24 of 25 trials were from the pre‐reperfusion era (published from 1974 to 1999), and only one trial was from the reperfusion era (published in 2018). The certainty of evidence was moderate to low for all outcomes. Our meta‐analyses show that beta‐blockers compared with placebo or no intervention probably reduce the risks of all‐cause mortality (risk ratio (RR) 0.81, 97.5% confidence interval (CI) 0.73 to 0.90; I² = 15%; 22,085 participants, 21 trials; moderate‐certainty evidence) and myocardial reinfarction (RR 0.76, 98% CI 0.69 to 0.88; I² = 0%; 19,606 participants, 19 trials; moderate‐certainty evidence). Our meta‐analyses show that beta‐blockers compared with placebo or no intervention may reduce the risks of major cardiovascular events (RR 0.72, 97.5% CI 0.69 to 0.84; 14,994 participants, 15 trials; low‐certainty evidence) and cardiovascular mortality (RR 0.73, 98% CI 0.68 to 0.85; I² = 47%; 21,763 participants, 19 trials; low‐certainty evidence). Hence, evidence seems to suggest that beta‐blockers versus placebo or no treatment may result in a minimum reduction of 10% in RR for risks of all‐cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction. However, beta‐blockers compared with placebo or no intervention may not affect the risk of angina (RR 1.04, 98% CI 0.93 to 1.13; I² = 0%; 7115 participants, 5 trials; low‐certainty evidence). No trials provided data on serious adverse events according to good clinical practice from the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH‐GCP), nor on quality of life. Authors' conclusions Beta‐blockers probably reduce the risks of all‐cause mortality and myocardial reinfarction in patients younger than 75 years of age without heart failure following acute myocardial infarction. Beta‐blockers may further reduce the risks of major cardiovascular events and cardiovascular mortality compared with placebo or no intervention in patients younger than 75 years of age without heart failure following acute myocardial infarction. These effects could, however, be driven by patients with unrecognised heart failure. The effects of beta‐blockers on serious adverse events, angina, and quality of life are unclear due to sparse data or no data at all. All trials and outcomes were at high risk of bias, and incomplete outcome data bias alone could account for the effect seen when major cardiovascular events, angina, and myocardial infarction are assessed. The evidence in this review is of moderate to low certainty, and the true result may depart substantially from the results presented here....

12 January 2022 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
SSSanam Safi
Sanam Safi
SSStephen P. Sanders
Stephen P. Sanders
MZMelissa Zhao
Melissa Zhao
CCChrystalle Katte Carreon
Chrystalle Katte Carreon
A maternally inherited novel pathogenic non-POU domain-containing octamer-binding gene variant c.767G>T, p.R256I [NM_001145408], manifested in a male infant as dilated cardiomyopathy with severe left ventricular dysfunction and dilation, biventricular non-compaction, tricuspid hypoplasia, and hydrocephaly. To the best of our knowledge, no previous non-POU domain-containing octamer-binding gene variants with biventricular non-compaction have been associated with tricuspid valve hypoplasia. Hence, this case introduces a new pathogenic variant observed in the non-POU domain-containing octamer-binding gene and adds to the range of cardiac phenotypes identified in non-POU domain-containing octamer-binding gene variants.

19 November 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
SSSanam Safi
Sanam Safi
VHVibeke E. Hjortdal
Vibeke E. Hjortdal
MGMarc Gewillig
Marc Gewillig
OMOwen Miller
Owen Miller
MAMohammad Ryan Abumehdi
Mohammad Ryan Abumehdi
CMColin J. McMahon
Colin J. McMahon
Background: Lymphatic disorders such as protein‐losing enteropathy, plastic bronchitis, and chylothorax are important complications of the Fontan circulation and ultimately result in an increased risk of early death. Several European centers are now performing lymphatic procedures. The aim of this study is to map the extent of these lymphatic disorders and treatments provided across European pediatric cardiology centers. Methods and Results: A survey was circulated to 49 European pediatric cardiology centers consisting of 37 questions including a mix of binary, categorical, and continuous variables. Thirty‐one centers (63%) participated in the study, performing a median of 250 (interquartile range, 178 ‐ 313) cardiopulmonary bypass procedures per year. Chylothorax emerged as the most prevalent lymphatic disorder followed by protein‐losing enteropathy and plastic bronchitis. The most common diagnostic investigation method was noncontrast magnetic resonance lymphangiography (52%). Eleven centers (35%) conducted lymphatic interventions with a median of 3 (interquartile range, 1 ‐ 4) procedures per year and 12 (interquartile range, 5 ‐ 15) interventions in total per center. Conclusions: This study confirms the rarity of and variation in treatment approaches for lymphatic disorders across Europe. With at least 11 centers offering lymphatic interventions, the adoption of these procedures is on the rise in Europe. To improve the quality of care and treatment outcomes for these complex patients, it is crucial to consider evidence‐based lymphatic diagnostics, interventional lymphatic procedures, and the centralization of services in Europe.

8 December 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SSSanam Safi
Sanam Safi
SKSteven Kwasi Korang
Steven Kwasi Korang
ENEmil Eik Nielsen
Emil Eik Nielsen
NSNaqash J Sethi
Naqash J Sethi
JFJoshua Feinberg
Joshua Feinberg
JJJanus C Jakobsen
Janus C Jakobsen